Abstract
Rapamycin (sirolimus) is an immunosuppressive drug approved by the Food and Drug Administration (FDA). It is also a leading candidate for targeting aging. Rapamycin and its analogs (everolimus, temsirolimus, ridaforolimus) inhibit the mammalian target of rapamycin (mTOR) kinase by binding to FK506-binding proteins (FKBP) and have a similar chemical structure that only differs in the functional group present at carbon-40. Analogs of rapamycin were developed to improve its pharmacological properties, such as low oral bioavailability and a long half-life. The analogs of rapamycin are referred to as "rapalogs."Rapamycin is the parent compound and should therewith not be called a "rapalog."
| Original language | English |
|---|---|
| Pages (from-to) | 657-659 |
| Number of pages | 3 |
| Journal | Gerontology |
| Volume | 69 |
| Issue number | 6 |
| Early online date | 6 Jun 2023 |
| DOIs | |
| Publication status | Published - Jun 2023 |
Bibliographical note
Funding Information:This article was funded by an unrestricted grant by the National University of Singapore and the Lien Foundation without any involvement in any parts of the work.
Publisher Copyright:
© 2023 Authors. All rights reserved.
Funding
This article was funded by an unrestricted grant by the National University of Singapore and the Lien Foundation without any involvement in any parts of the work.
Keywords
- Aging
- Mammalian target of rapamycin inhibitors
- Sirolimus
Fingerprint
Dive into the research topics of 'Why Is Rapamycin Not a Rapalog?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver